Brief: Arch Biopartners Discloses New Patent Filing For Novel Drug Candidates To Prevent Lung Inflammation
24/03/2020 12:45
March 24 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS DISCLOSES NEW PATENT FILING FOR NOVEL
DRUG
CANDIDATES TO PREVENT LUNG INFLAMMATION
* ARCH BIOPARTNERS - EVALUATING POSSIBILITIES TO USE
METABLOK IN
PHASE II TRIAL FOR LUNG INFLAMMATION DUE TO VIRAL PNEUMONIA IN
COVID-19 INFECTED PATIENTS
Source text for Eikon: ID:nGNX5FScFF
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide